A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 1120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Actual Study Start Date: September 5, 2018
Estimated Primary Completion Date: May 2021
Estimated Study Completion Date: May 2021

Arms:
- Experimental: Bimekizumab dose regimen 1
- Experimental: Bimekizumab dose regimen 2